Visit
VJSocial
Marco Herling of @UniLeipzig discusses the safety and efficacy of tagraxofusp for the treatment of BPDCN:
🎥: http://ow.ly/hq9y50JGpAF
@EHA_Hematology #EHA2022 #RareDiseases #BPDCN
📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!
🎧: http://ow.ly/Rmji50JGF6U
#MMsm #HemOnc #Myeloma
📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!
🎧: http://ow.ly/Rmji50JGF6U
#MMsm #HemOnc #Myeloma
On June 24, the @US_FDA approved lisocabtagene maraleucel (liso-cel) for second-line treatment of adult patients with LBCL. The efficacy of liso-cel has been evaluated in the TRANSFORM study.
Find out more here:
👉http://ow.ly/QqNu50JJj3z👈
#LymSM #HemOnc #CARTcell #ImmunoOnc
VJSocial
At this year's EHA meeting, we spoke with leading experts about what was trending on Twitter and how you can make the most out of Twitter in your professional role.
Learn how to make the most out of Twitter in your professional role and stay up to date with what's trending at EHA 2021.
During this year's EHA meeting, VJSocial will be hosting a series of social media masterclasses to discuss trending topics across the spectrum of hematological malignancies and help hematologists, researchers, nurses, and allied medical professionals learn how to leverage the power of Twitter in their professional roles.
Marco Herling of @UniLeipzig discusses the safety and efficacy of tagraxofusp for the treatment of BPDCN:
🎥: http://ow.ly/hq9y50JGpAF
@EHA_Hematology #EHA2022 #RareDiseases #BPDCN
📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!
🎧: http://ow.ly/Rmji50JGF6U
#MMsm #HemOnc #Myeloma
📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!
🎧: http://ow.ly/Rmji50JGF6U
#MMsm #HemOnc #Myeloma
On June 24, the @US_FDA approved lisocabtagene maraleucel (liso-cel) for second-line treatment of adult patients with LBCL. The efficacy of liso-cel has been evaluated in the TRANSFORM study.
Find out more here:
👉http://ow.ly/QqNu50JJj3z👈
#LymSM #HemOnc #CARTcell #ImmunoOnc
VJHemOnc is intended for Healthcare Professionals onlyBy choosing to continue, you are confirming that you are a healthcare professional
Sign-up for our Newsletter!
Keep up to date with all the latest news with our monthly newsletter
